Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
|
N Engl J Med
|
2008
|
43.36
|
2
|
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
|
Lancet
|
2009
|
10.52
|
3
|
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.
|
Lancet
|
2012
|
4.46
|
4
|
A randomized trial of rosuvastatin in the prevention of venous thromboembolism.
|
N Engl J Med
|
2009
|
4.46
|
5
|
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
|
Circulation
|
2010
|
4.37
|
6
|
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
|
Lancet
|
2010
|
4.07
|
7
|
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.
|
Circulation
|
2013
|
3.03
|
8
|
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
|
Circulation
|
2013
|
3.02
|
9
|
Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.
|
J Am Coll Cardiol
|
2010
|
2.93
|
10
|
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.
|
Nature
|
2013
|
2.46
|
11
|
Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
|
Circulation
|
2009
|
1.97
|
12
|
Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial.
|
JAMA Intern Med
|
2015
|
1.61
|
13
|
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
|
Circ Cardiovasc Qual Outcomes
|
2009
|
1.46
|
14
|
Estimating treatment effects for individual patients based on the results of randomised clinical trials.
|
BMJ
|
2011
|
1.32
|
15
|
Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
|
Circ Cardiovasc Genet
|
2011
|
1.32
|
16
|
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
|
J Am Coll Cardiol
|
2012
|
1.11
|
17
|
Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk".
|
Circ Cardiovasc Qual Outcomes
|
2010
|
1.09
|
18
|
Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER).
|
Am J Cardiol
|
2014
|
0.86
|
19
|
High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy.
|
Circulation
|
2015
|
0.86
|
20
|
Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities.
|
Eur Heart J
|
2010
|
0.83
|
21
|
Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
|
Am Heart J
|
2011
|
0.83
|
22
|
Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
|
Circulation
|
2015
|
0.83
|
23
|
Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk.
|
Circ Res
|
2016
|
0.83
|
24
|
Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents.
|
Eur Heart J
|
2016
|
0.82
|
25
|
To JUPITER and beyond: statins, inflammation, and primary prevention.
|
Crit Care
|
2010
|
0.82
|
26
|
Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial.
|
J Am Heart Assoc
|
2016
|
0.81
|
27
|
Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
|
JAMA Cardiol
|
2016
|
0.80
|
28
|
C-reactive protein levels in patients at cardiovascular risk: EURIKA study.
|
BMC Cardiovasc Disord
|
2014
|
0.79
|
29
|
Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program.
|
Atherosclerosis
|
2012
|
0.78
|
30
|
Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures.
|
Circ Cardiovasc Genet
|
2015
|
0.75
|
31
|
Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial.
|
J Am Heart Assoc
|
2020
|
0.75
|